Belgian medical experts are urging Riziv, the National Institute for Health and Disability Insurance, to reimburse new monoclonal antibody treatments for early-stage Alzheimer’s. These therapies target amyloid-beta plaques to slow cognitive decline, marking a pivotal shift from purely palliative care to disease-modifying interventions for eligible patients.
For decades, the clinical approach to Alzheimer’s disease was limited to managing symptoms—treating the agitation, memory loss, and depression that accompany neurodegeneration. The current push for reimbursement in Belgium reflects a global tension between groundbreaking science and the economic realities of public health. We are no longer talking about “slowing the inevitable” through lifestyle changes alone; we are discussing the deployment of biologics that physically alter the pathology of the brain.
In Plain English: The Clinical Takeaway
- Not a Cure: These drugs do not reverse dementia or “fix” the brain; they slow down the rate at which a patient loses their independence and memory.
- Early Window: These treatments only function for people in the very early stages of the disease (Mild Cognitive Impairment). Once significant damage is done, the drugs are ineffective.
- High Maintenance: This is not a pill. It requires regular intravenous (IV) infusions and frequent MRI scans to ensure the drug isn’t causing dangerous brain swelling.
The Molecular Mechanism: Clearing the Amyloid Fog
The treatments currently under debate—primarily lecanemab and donanemab—operate via a mechanism of action (the specific biochemical process through which a drug produces its effect) known as monoclonal antibody therapy. These are laboratory-engineered proteins designed to seek out and bind to amyloid-beta plaques.
Amyloid-beta is a protein fragment that clumps together in the brains of Alzheimer’s patients, forming “plaques” that disrupt cell-to-cell communication and eventually trigger neuronal death. By tagging these plaques, the drugs signal the body’s own immune system (specifically microglia) to clear the debris. This process aims to preserve the synaptic integrity of the brain for a longer period.
However, the “Amyloid Hypothesis”—the theory that clearing these plaques is the key to stopping Alzheimer’s—remains a subject of intense academic debate. While double-blind placebo-controlled trials (studies where neither the patient nor the doctor knows who is receiving the drug) show a statistically significant slowing of decline, the “clinical significance”—how much a patient actually feels the difference in daily life—is more modest, typically slowing decline by roughly 27% to 35% over 18 months.
Global Regulatory Divergence: FDA vs. EMA vs. Riziv
The struggle for reimbursement in Belgium mirrors a fragmented global landscape. In the United States, the FDA granted traditional approval to lecanemab, prioritizing patient access to potentially disease-modifying therapy. Conversely, the European Medicines Agency (EMA) has maintained a more cautious stance, frequently citing concerns over the risk-benefit ratio.
The primary hurdle for European bodies like Riziv is the cost-effectiveness threshold. When a drug costs tens of thousands of dollars per year and provides a modest delay in nursing home admission, health economists must decide if that expenditure outweighs other public health priorities. In the UK, NICE (National Institute for Health and Care Excellence) has historically been restrictive with these therapies, emphasizing that the marginal benefit may not justify the systemic cost.
“The challenge we face is not just biological, but infrastructural. To deploy these drugs safely, we need a massive increase in PET scan availability and MRI capacity to monitor for adverse events. Without the infrastructure, the drug is a liability, not a therapy.” — Dr. Sebastian Koehler, Neurologist and Clinical Researcher.
Comparative Efficacy and Safety Profiles
To understand why experts are calling these a “turning point,” we must look at the data. The following table summarizes the key clinical distinctions between the leading amyloid-targeting therapies based on Phase III trial data.
| Metric | Lecanemab (Leqembi) | Donanemab (Kisunla) |
|---|---|---|
| Target | Amyloid-beta protofibrils | Established amyloid plaques |
| Primary Endpoint | ~27% slower decline (CDR-SB) | ~35% slower decline (iADRS) |
| Administration | Bi-weekly IV infusion | Monthly IV infusion |
| Primary Risk | ARIA-E (Brain Edema) | ARIA-H (Microhemorrhages) |
| Trial Funding | Eisai & Biogen | Eli Lilly |
The ARIA Risk: A Necessary Clinical Caution
The most significant safety concern associated with these therapies is ARIA (Amyloid-Related Imaging Abnormalities). ARIA-E refers to edema (swelling) in the brain, while ARIA-H refers to microhemorrhages (tiny bleeds). While many patients are asymptomatic, some experience headaches, confusion, or, in rare cases, severe neurological deficits.
The risk is significantly higher for patients who carry the APOE $\epsilon$4 allele, a genetic variant that increases Alzheimer’s susceptibility. This necessitates genetic screening before treatment begins, adding another layer of cost and complexity to the clinical pathway.
Contraindications & When to Consult a Doctor
These treatments are not suitable for all patients. Absolute contraindications (conditions where the drug must not be used) include:
- Concurrent Anticoagulant Apply: Patients on blood thinners (e.g., warfarin or apixaban) face a significantly higher risk of catastrophic brain hemorrhage during amyloid clearance.
- Advanced Dementia: Patients in the moderate to severe stages of Alzheimer’s do not benefit from these drugs and are exposed to risks without reward.
- Severe Vascular Disease: Those with a history of multiple strokes or significant cerebral amyloid angiopathy (CAA) are generally excluded.
Consult a neurologist immediately if a patient on these therapies exhibits sudden onset of severe headache, new confusion, or visual disturbances, as these are hallmark signs of ARIA.
The Path Forward: Toward Combination Therapy
The current push for Riziv reimbursement is the first step toward a future of “combination therapy.” Much like the treatment of HIV or cancer, the medical community expects that clearing amyloid is only one piece of the puzzle. Future protocols will likely combine amyloid-clearers with tau-protein inhibitors (targeting the “tangles” inside neurons) and neuro-inflammatory modulators.
While the financial burden on the Belgian healthcare system is substantial, the cost of inaction—the long-term care of millions of patients with advanced dementia—is higher. The transition to a disease-modifying model is inevitable; the only remaining question is how quickly the regulatory and financial frameworks can adapt to keep pace with the science.
